PCSK9 and coronary artery disorder: The IVW results also indicated that PCSK9 inhibition decreased the risk of CHD: Per 1 standard deviation (SD, mg/dL) decrease in low-density lipoprotein cholesterol (LDL-C) was associated with a 40.3% reduction in CHD risk (GWAS ID: ieu-a-7) (odds ratio (OR) = 0.597; 95% confidence interval (CI) = 0.525–0.680; P = 7.998 × 10−15), and 42.6% reduction in CHD risk (GWAS ID: ebi-a-GCST000998) (OR = 0.574; 95% CI = 0.452–0.730; P = 6.104 × 10−6), respectively.